Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

TDF-based ART best, but too costly for resource-poor Lesotho?

    • 11 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    TDF-based ART best, but too costly for resource-poor Lesotho?. Pharmacoecon. Outcomes News 634, 10 (2011). https://doi.org/10.2165/00151234-201106340-00026

    Download citation

    Keywords

    • Zidovudine
    • Incremental Cost
    • Tenofovir
    • Stavudine
    • Resource Limited Setting